Vanguard Fiduciary Trust
DRUG

Vanguard Fiduciary Trust’s Bright Minds Biosciences DRUG Stock Holding History

Vanguard Fiduciary Trust’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$491K Buy
7,001
+939
+15% +$73.7K ﹤0.01% 3280
2026
Q1 		$442K Buy
+6,062
New +$488K ﹤0.01% 3249

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Fiduciary Trust's DRUG Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Bright Minds Biosciences (DRUG) stake by 15% in Q2 2026, buying an estimated $73.7K and bringing the position to 7,001 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #3280.

Vanguard Fiduciary Trust first reported a position in DRUG in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Vanguard Fiduciary Trust held 7,001 shares of Bright Minds Biosciences worth $491K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 939 Bright Minds Biosciences shares in Q2 2026, an estimated $73.7K.
  • Bright Minds Biosciences made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3280 holding.
  • Vanguard Fiduciary Trust first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.